<p>Qube Research
&amp; Technologies Ltd 在第二季度收购了 Penumbra, Inc.（纽约证券交易所代码：PEN - 免费报告）的新股份，具体信息在其最近向证券交易委员会的备案中披露。该基金收购了 209,710 股公司股票，价值约为 53,818,000 美元。截至其最近向证券交易委员会的备案，Qube Research
&amp; Technologies Ltd 拥有 Penumbra 约 0.54% 的股份。</p>
<ul>
<li>3 只中型医疗股表现优于市场</li>
</ul>
<p>其他对冲基金最近也调整了对该公司的持股。Vanguard Group Inc. 在第二季度将其在 Penumbra 的持股增加了 5.0%。Vanguard Group Inc. 目前拥有 3,860,655 股公司股票，价值 990,760,000 美元，此前在上个季度又购买了 185,306 股。Geode Capital Management LLC 在第二季度将其在 Penumbra 的持股增加了 2.6%。Geode Capital Management LLC 目前拥有 706,404 股公司股票，价值 181,314,000 美元，此前在此期间又收购了 17,772 股。摩根大通在第一季度将其在 Penumbra 的持股增加了 437.0%。摩根大通目前拥有 703,634 股公司股票，价值 188,159,000 美元，此前在上个季度又收购了 572,606 股。Invesco Ltd. 在第二季度将其在 Penumbra 的持股增加了 1,139.3%。Invesco Ltd. 目前拥有 633,485 股公司股票，价值 162,571,000 美元，此前在上个季度又购买了 582,369 股。最后，挪威银行在第二季度收购了价值约 114,014,000 美元的 Penumbra 新股份。对冲基金和其他机构投资者目前持有该公司 88.88% 的股份。</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司对 PEN 发表了看法。BTIG Research 在 10 月 27 日的研究报告中重申了对 Penumbra 的 “买入” 评级，并设定了 320.00 美元的目标价。Evercore ISI 在 11 月 6 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 286.00 美元的目标价。花旗集团将 Penumbra 的评级从 “中性” 上调至 “买入”，并将其目标价从 285.00 美元提高至 350.00 美元。富国银行在 11 月 18 日的研究报告中开始覆盖 Penumbra，并对该股票给予了 “减持” 评级。最后，Wall Street Zen 在 11 月 1 日的研究报告中将 Penumbra 的评级从 “买入” 下调至 “持有”。一位投资分析师对该股票给予了强烈买入评级，十三位分析师给予了买入评级，三位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Penumbra 目前的共识评级为 “适度买入”，共识目标价为 309.75 美元。</p>
<ul>
<li>这些医疗设备制造商准备反弹吗？</li>
</ul>
<p><strong>查看我们对 Penumbra 的最新股票分析</strong></p>
<h2>Penumbra 股价上涨 3.0%</h2>
<p>Penumbra 股票在周五开盘价为 312.01 美元。Penumbra, Inc. 的一年最低价为 221.26 美元，一年最高价为 314.74 美元。该公司的 50 日移动平均价格为 267.92 美元，200 日移动平均价格为 258.93 美元。公司的债务与股本比率为 0.02，流动比率为 6.73，速动比率为 4.18。公司的市值为 122.2 亿美元，市盈率为 74.64，PEG 比率为 2.50，贝塔值为 0.66。</p>
<p>Penumbra（纽约证券交易所代码：PEN - 获取免费报告）最近在 11 月 5 日宣布了其季度财报。该公司报告本季度每股收益为 0.97 美元，超出分析师共识预期的 0.90 美元，超出 0.07 美元。该公司本季度的收入为 3.5469 亿美元，而分析师预期为 3.4077 亿美元。Penumbra 的股本回报率为 11.35%，净利润率为 12.30%。该公司的季度收入较去年同期增长了 17.8%。在去年同期，该公司每股收益为 0.85 美元。分析师平均预测 Penumbra, Inc. 本财年每股收益将达到 3.67 美元。</p>
<h2>内部买卖</h2>
<p>在相关消息中，执行副总裁 Johanna Roberts 于 12 月 5 日星期五出售了 300 股公司的股票。股票以平均价格 300.13 美元出售，总交易额为 90,039.00 美元。交易完成后，该执行副总裁直接持有 63,836 股公司股票，价值约为 19,159,098.68 美元。这代表其持股减少了 0.47%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，董事 Arani Bose 于 11 月 25 日星期二出售了 7,500 股公司的股票。股票以平均价格 300.19 美元出售，总交易额为 2,251,425.00 美元。交易完成后，该董事在公司持有 275,261 股，价值 82,630,599.59 美元。该交易使其持股减少了 2.65%。该交易的披露信息可在证券交易委员会的备案中找到。在过去的九十天里，内部人士出售了价值 5,755,174 美元的 19,744 股公司股票。目前，内部人士持有该股票的 4.20%。</p>
<h2>Penumbra 公司简介</h2>
<p>（免费报告）</p>
<p>Penumbra, Inc. 及其子公司在美国和国际上设计、开发、制造和销售医疗设备。该公司提供外周产品，包括用于体内血栓动力吸引的 Indigo 系统；Lightning Flash，一种机械性血栓切除系统；Lightning Bolt 7，一种动脉血栓切除系统；以及 CAT RX。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Penumbra</li>
<li>深入分析买卖价差</li>
<li>2026 年需避免的三只最近被下调评级的股票</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>芯片热潮回归：三只有望获得巨大收益的股票</li>
<li>我在哪里可以找到 52 周的最高和最低点？</li>
<li>Oracle 股票遭重创：其 AI 管道为何可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Penumbra 吗？</h2>
<p>在考虑 Penumbra 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而 Penumbra 并不在名单上。</p>
<p>虽然 Penumbra 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Qube Research & Technologies Ltd 在第二季度收购了 Penumbra, Inc. 的新头寸，购买了 209,710 股，价值约为 5382 万美元。这次收购占 Penumbra 股票的 0.54%。其他对冲基金也增加了对 Penumbra 的持股。分析师为 Penumbra 设置了新的价格目标，普遍评级为 “适度买入”，共识价格目标为 309.75 美元。Penumbra 的股票最近交易价格为 312.01 美元，市值为 122.2 亿美元</p>

<p>Qube Research &amp; Technologies Ltd acquired a new position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 209,710 shares of the company's stock, valued at approximately $53,818,000. Qube Research &amp; Technologies Ltd owned approximately 0.54% of Penumbra as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Qube Research
&amp; Technologies Ltd 在第二季度收购了 Penumbra, Inc.（纽约证券交易所代码：PEN - 免费报告）的新股份，具体信息在其最近向证券交易委员会的备案中披露。该基金收购了 209,710 股公司股票，价值约为 53,818,000 美元。截至其最近向证券交易委员会的备案，Qube Research
&amp; Technologies Ltd 拥有 Penumbra 约 0.54% 的股份。</p>
</div><ul>
<li>3 Mid-Cap Medical Stocks Outperforming the Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只中型医疗股表现优于市场</li>
</ul>
</div><p>Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Penumbra by 5.0% during the second quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company's stock valued at $990,760,000 after buying an additional 185,306 shares in the last quarter. Geode Capital Management LLC boosted its position in Penumbra by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 706,404 shares of the company's stock worth $181,314,000 after acquiring an additional 17,772 shares during the period. JPMorgan Chase &amp; Co. grew its stake in Penumbra by 437.0% during the 1st quarter. JPMorgan Chase &amp; Co. now owns 703,634 shares of the company's stock valued at $188,159,000 after acquiring an additional 572,606 shares in the last quarter. Invesco Ltd. lifted its position in shares of Penumbra by 1,139.3% in the second quarter. Invesco Ltd. now owns 633,485 shares of the company's stock worth $162,571,000 after purchasing an additional 582,369 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Penumbra during the second quarter worth approximately $114,014,000. Hedge funds and other institutional investors own 88.88% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金最近也调整了对该公司的持股。Vanguard Group Inc. 在第二季度将其在 Penumbra 的持股增加了 5.0%。Vanguard Group Inc. 目前拥有 3,860,655 股公司股票，价值 990,760,000 美元，此前在上个季度又购买了 185,306 股。Geode Capital Management LLC 在第二季度将其在 Penumbra 的持股增加了 2.6%。Geode Capital Management LLC 目前拥有 706,404 股公司股票，价值 181,314,000 美元，此前在此期间又收购了 17,772 股。摩根大通在第一季度将其在 Penumbra 的持股增加了 437.0%。摩根大通目前拥有 703,634 股公司股票，价值 188,159,000 美元，此前在上个季度又收购了 572,606 股。Invesco Ltd. 在第二季度将其在 Penumbra 的持股增加了 1,139.3%。Invesco Ltd. 目前拥有 633,485 股公司股票，价值 162,571,000 美元，此前在上个季度又购买了 582,369 股。最后，挪威银行在第二季度收购了价值约 114,014,000 美元的 Penumbra 新股份。对冲基金和其他机构投资者目前持有该公司 88.88% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms have weighed in on PEN. BTIG Research reiterated a &#34;buy&#34; rating and issued a $320.00 price objective on shares of Penumbra in a research note on Monday, October 27th. Evercore ISI reaffirmed an &#34;outperform&#34; rating and issued a $286.00 price target on shares of Penumbra in a research note on Thursday, November 6th. Citigroup raised Penumbra from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price objective for the company from $285.00 to $350.00 in a research report on Thursday. Wells Fargo &amp; Company started coverage on Penumbra in a research note on Tuesday, November 18th. They issued an &#34;underweight&#34; rating on the stock. Finally, Wall Street Zen downgraded Penumbra from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Penumbra presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $309.75.</p>
<div class="lb-trans"><p>几家研究公司对 PEN 发表了看法。BTIG Research 在 10 月 27 日的研究报告中重申了对 Penumbra 的 “买入” 评级，并设定了 320.00 美元的目标价。Evercore ISI 在 11 月 6 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 286.00 美元的目标价。花旗集团将 Penumbra 的评级从 “中性” 上调至 “买入”，并将其目标价从 285.00 美元提高至 350.00 美元。富国银行在 11 月 18 日的研究报告中开始覆盖 Penumbra，并对该股票给予了 “减持” 评级。最后，Wall Street Zen 在 11 月 1 日的研究报告中将 Penumbra 的评级从 “买入” 下调至 “持有”。一位投资分析师对该股票给予了强烈买入评级，十三位分析师给予了买入评级，三位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Penumbra 目前的共识评级为 “适度买入”，共识目标价为 309.75 美元。</p>
</div><ul>
<li>Are These Medical Device Makers Getting Ready To Rally?</li>
</ul>
<div class="lb-trans"><ul>
<li>这些医疗设备制造商准备反弹吗？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Penumbra</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Penumbra 的最新股票分析</strong></p>
</div><h2>Penumbra Trading Up 3.0%</h2>
<div class="lb-trans"><h2>Penumbra 股价上涨 3.0%</h2>
</div><p>Penumbra stock opened at $312.01 on Friday. Penumbra, Inc. has a one year low of $221.26 and a one year high of $314.74. The company's fifty day moving average price is $267.92 and its two-hundred day moving average price is $258.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. The company has a market capitalization of $12.22 billion, a price-to-earnings ratio of 74.64, a PEG ratio of 2.50 and a beta of 0.66.</p>
<div class="lb-trans"><p>Penumbra 股票在周五开盘价为 312.01 美元。Penumbra, Inc. 的一年最低价为 221.26 美元，一年最高价为 314.74 美元。该公司的 50 日移动平均价格为 267.92 美元，200 日移动平均价格为 258.93 美元。公司的债务与股本比率为 0.02，流动比率为 6.73，速动比率为 4.18。公司的市值为 122.2 亿美元，市盈率为 74.64，PEG 比率为 2.50，贝塔值为 0.66。</p>
</div><p>Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to analysts' expectations of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The business's quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.85 earnings per share. On average, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Penumbra（纽约证券交易所代码：PEN - 获取免费报告）最近在 11 月 5 日宣布了其季度财报。该公司报告本季度每股收益为 0.97 美元，超出分析师共识预期的 0.90 美元，超出 0.07 美元。该公司本季度的收入为 3.5469 亿美元，而分析师预期为 3.4077 亿美元。Penumbra 的股本回报率为 11.35%，净利润率为 12.30%。该公司的季度收入较去年同期增长了 17.8%。在去年同期，该公司每股收益为 0.85 美元。分析师平均预测 Penumbra, Inc. 本财年每股收益将达到 3.67 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, EVP Johanna Roberts sold 300 shares of the company's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the sale, the executive vice president directly owned 63,836 shares of the company's stock, valued at approximately $19,159,098.68. This represents a 0.47% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Arani Bose sold 7,500 shares of the firm's stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $300.19, for a total transaction of $2,251,425.00. Following the completion of the transaction, the director owned 275,261 shares in the company, valued at $82,630,599.59. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 19,744 shares of company stock worth $5,755,174. 4.20% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Johanna Roberts 于 12 月 5 日星期五出售了 300 股公司的股票。股票以平均价格 300.13 美元出售，总交易额为 90,039.00 美元。交易完成后，该执行副总裁直接持有 63,836 股公司股票，价值约为 19,159,098.68 美元。这代表其持股减少了 0.47%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，董事 Arani Bose 于 11 月 25 日星期二出售了 7,500 股公司的股票。股票以平均价格 300.19 美元出售，总交易额为 2,251,425.00 美元。交易完成后，该董事在公司持有 275,261 股，价值 82,630,599.59 美元。该交易使其持股减少了 2.65%。该交易的披露信息可在证券交易委员会的备案中找到。在过去的九十天里，内部人士出售了价值 5,755,174 美元的 19,744 股公司股票。目前，内部人士持有该股票的 4.20%。</p>
</div><h2>Penumbra Company Profile</h2>
<div class="lb-trans"><h2>Penumbra 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.</p>
<div class="lb-trans"><p>Penumbra, Inc. 及其子公司在美国和国际上设计、开发、制造和销售医疗设备。该公司提供外周产品，包括用于体内血栓动力吸引的 Indigo 系统；Lightning Flash，一种机械性血栓切除系统；Lightning Bolt 7，一种动脉血栓切除系统；以及 CAT RX。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Penumbra</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Penumbra</li>
<li>深入分析买卖价差</li>
<li>2026 年需避免的三只最近被下调评级的股票</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>芯片热潮回归：三只有望获得巨大收益的股票</li>
<li>我在哪里可以找到 52 周的最高和最低点？</li>
<li>Oracle 股票遭重创：其 AI 管道为何可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PEN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Penumbra Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Penumbra 吗？</h2>
</div><p>Before you consider Penumbra, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Penumbra 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而 Penumbra 并不在名单上。</p>
</div><p>While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Penumbra 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Qube Research & Technologies Ltd 向 Penumbra, Inc. $PEN 投资了 5382 万美元